Marine Linear Peptides: Isolation, Structure, Biological Properties, Synthesis, Biosynthesis, and Current Advances in Therapeutics
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 9081
Special Issue Editor
Interests: marine natural product chemistry; marine sponges; marine microbiology; marine chemical ecology; bioactivity; antifouling, anti-biofilm compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The extraordinary biodiversity of the marine world has already offered thousands of varied compounds, such as steroids and terpenoids, alkaloids, polyketides, peptides, etc. The latter represent a large family of marine compounds with a broad spectrum of properties ranging from anticancer to antimicrobial, antioxidant, and anti-inflammatory activities. Marine linear peptides have been particularly successful, leading to two marketed drugs, ziconotide (Prialt®) and Brentuximab vedotin (Adcetris®).
Ziconotide, also known as ω-conotoxin MVIIA, is a 25 amino acid peptide with three disulfide linkages that was clinically approved by the US Food and Drug Administration (FDA) in December 2004 for the intrathecal treatment of severe chronic pain. Ziconotide was shown to block the entry of calcium into neuronal N-type voltage-sensitive calcium channels.
Brentuximab vedotin, a peptide-derived from dolastatin-10 analogue (monomethyl auristatin E), belongs to the very exciting anticancer class of antibody–drug conjugates (ADCs). Brentuximab vedotin is used for the treatment of relapsed or refractory CD30-positive Hodgkin's lymphoma. So far, five other ADCs have been marketed and 16 ADCs are in clinical trials, at various stages of development. They represent an extremely promising avenue for new molecules with potential anticancer activities.
More recently, gallinamide A, an unusual linear peptide isolated from marine cyanobacteria, known as a potent and selective inhibitor of human cathepsin L, revealed anti-SRAS-CoV2 activity with EC50 values in the nanomolar range.
These successful and growing promises of linear peptides in human therapies have led us to propose a Special Issue entitled “Marine Linear Peptides” to showcase the remarkable family of linear peptides from marine macroorganisms and microorganisms such as cyanobacteria and actinomycetes, including the innovative methodologies used for their identifications, as well as their biological properties and synthesis or biosynthesis. Their potential applications as pharmaceuticals or nutraceuticals will be developed. The progression of some peptide-derived products to clinical trial development should provide to the marine scientist community exciting recent information regarding these attractive families of natural products.
Dr. Marie-Lise Bourguet-Kondracki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Marine linear peptides
- Conotoxin
- Marine cyanobacteria
- Marine actinomycetes
- Biological activity
- Pharmaceuticals
- Nutraceuticals
- Marine natural products
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
